lestaurtinib has been researched along with Acute Lymphoid Leukemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borowitz, MJ; Brown, PA; Carroll, AJ; Carroll, WL; Devidas, M; Dreyer, ZE; Gore, L; Heerema, NA; Hilden, JM; Hunger, SP; Kairalla, JA; Loh, ML; Raetz, EA; Salzer, WL; Small, D; Wang, C; Winick, NJ | 1 |
| Breen, M; Richards, KL; Seiser, EL; Small, GW; Suter, SE; Thomas, R | 1 |
| Brown, P; Campana, D; Downing, J; Levis, M; Shurtleff, S; Small, D | 1 |
| Zhang, GS | 1 |
| Brown, P; Griesemer, M; Levis, M; McIntyre, E; Small, D | 1 |
1 trial(s) available for lestaurtinib and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Female; fms-Like Tyrosine Kinase 3; Furans; Histone-Lysine N-Methyltransferase; Humans; Infant; Male; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors | 2021 |
4 other study(ies) available for lestaurtinib and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
FLT3 mutations in canine acute lymphocytic leukemia.
Topics: Amino Acid Sequence; Animals; Blotting, Western; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA Mutational Analysis; DNA, Neoplasm; Dogs; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Furans; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; STAT5 Transcription Factor | 2011 |
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
Topics: Age Factors; Apoptosis; Carbazoles; Child; DNA-Binding Proteins; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Gene Expression Regulation, Leukemic; Gene Rearrangement; Genotype; Histone-Lysine N-Methyltransferase; Humans; Indoles; Infant; Myeloid-Lymphoid Leukemia Protein; Phenotype; Ploidies; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogenes; Receptor Protein-Tyrosine Kinases; Transcription Factors; Tumor Cells, Cultured | 2005 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Drug Synergism; fms-Like Tyrosine Kinase 3; Furans; G1 Phase; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Indoles; Infant; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors | 2006 |